HC Wainwright Issues Negative Forecast for RYTM Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Equities research analysts at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Rhythm Pharmaceuticals in a research report issued to clients and investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.74) per share for the quarter, down from their prior forecast of ($0.68). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q2 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.87) EPS and Q1 2026 earnings at ($0.60) EPS.

A number of other analysts have also commented on the stock. Stifel Nicolaus started coverage on shares of Rhythm Pharmaceuticals in a research note on Wednesday, March 5th. They issued a “buy” rating and a $78.00 price target for the company. Oppenheimer assumed coverage on shares of Rhythm Pharmaceuticals in a research report on Friday, December 20th. They issued an “outperform” rating and a $76.00 target price for the company. Needham & Company LLC increased their price target on Rhythm Pharmaceuticals from $64.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, March 18th. Jefferies Financial Group began coverage on Rhythm Pharmaceuticals in a report on Thursday, January 2nd. They issued a “buy” rating and a $80.00 price objective for the company. Finally, JMP Securities reissued a “market outperform” rating and issued a $75.00 target price on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $69.46.

Rhythm Pharmaceuticals Stock Performance

Shares of NASDAQ:RYTM opened at $53.49 on Wednesday. The firm has a market cap of $3.38 billion, a price-to-earnings ratio of -12.35 and a beta of 2.30. The business has a 50-day simple moving average of $55.25 and a two-hundred day simple moving average of $55.00. Rhythm Pharmaceuticals has a fifty-two week low of $35.17 and a fifty-two week high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The business had revenue of $41.83 million during the quarter, compared to analysts’ expectations of $38.48 million.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. SRS Capital Advisors Inc. boosted its stake in shares of Rhythm Pharmaceuticals by 740.7% in the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock worth $25,000 after acquiring an additional 400 shares during the period. Raleigh Capital Management Inc. bought a new position in Rhythm Pharmaceuticals in the 4th quarter worth approximately $28,000. SBI Securities Co. Ltd. purchased a new stake in Rhythm Pharmaceuticals during the 4th quarter valued at approximately $37,000. R Squared Ltd bought a new stake in shares of Rhythm Pharmaceuticals during the fourth quarter valued at approximately $44,000. Finally, State of Wyoming purchased a new position in shares of Rhythm Pharmaceuticals in the fourth quarter worth $61,000.

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, insider Joseph Shulman sold 1,281 shares of Rhythm Pharmaceuticals stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $59.43, for a total transaction of $76,129.83. Following the transaction, the insider now owns 2,657 shares in the company, valued at approximately $157,905.51. The trade was a 32.53 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Yann Mazabraud sold 75,000 shares of the company’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the completion of the transaction, the executive vice president now directly owns 40,370 shares of the company’s stock, valued at $2,078,247.60. This represents a 65.01 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 108,131 shares of company stock valued at $5,781,098. Company insiders own 5.60% of the company’s stock.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.